← Back to Treatments
🏅 FDA Orphan Designation

CytoGam

Cytomegalovirus immune globulin (human)

Manufacturer: CSL Behring LLC

Indicated for:
Severe disseminated cytomegalovirus infection in immunocompetent patientsOrphanRecurrent hepatitis C virus induced liver disease in liver transplant recipients

FDA-Approved Indications (2)

#1) Attenuation of primary CMV disease associated with kidney transplant recipients who are seronegative for CMV and who receive a kidney from a CMV seropositve donor; #2) Prophylaxis of CMV disease a…

Attenuation of primary CMV disease associated with kidney transplant recipients who are seronegative for CMV and who receive a kidney from a CMV seropositve donor

Population: kidney transplant recipients who are CMV seronegative receiving kidney from CMV seropositive donor

Indications & Usage

#1) Attenuation of primary CMV disease associated with kidney transplant recipients who are seronegative for CMV and who receive a kidney from a CMV seropositve donor; #2) Prophylaxis of CMV disease associated transplantation of kidney (all other), lung, liver, pancreas and heart.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.